Clinical Study Of Endostar Combined With Cisplatin In The Treatment Of Lung Cancer With Malignant Pleural Effusion

Objective:Efficacy of Endostar combined with cisplatin in the treatment of lung cancer,malignant chest water safety.At the same time, the quality of life of curative effect,combined with cisplatin Endostar group compared with single agent cisplatin group toimprove the situation and adverse reaction.Methods: from December1,2012~2014year in December1st confirmed (prior hadconfirmed cases included) a total of48patients with malignant pleural effusion withlung cancer, the treatment group22cases, single agent cisplatin group26cases, thetreatment group were12male patients,10female patients, in14cases of control groupin male patients,12female, age39~75years old, median age58years, were receivedconventional chemotherapy of patients with lung cancer, non small cell lung cancer(NSCLC) and small cell lung cancer (SCLC) patients were35and13cases, including22cases of NSCLC and SCLC were16cases,6cases of treatment group, the single agentcisplatin group NSCLC and SCLC were respectively19cases,7cases.All patients withpleural effusion amount is large, and a great deal of hydrothorax accounted for the vastmajority,22cases in treatment group were only1cases of pleural effusion in patientswith single agent cisplatin group,26patients in2cases of pleural effusionIn.48casesof lung cancer with malignant pleural effusion, pleural fluid to exhaust, givenantiemetic protecting stomach medicine pretreatment,22patients in treatment groupwere treated with Recombinant Human Endostatin Injection (Endostar)30mg afterinjection into the thoracic cavity and given20ml saline plus cisplatin50mg injection into the thoracic cavity, single agent cisplatin intrapleural30ML physiology saline pluscisplatin50mg, postoperative were given10ml normal saline flush tube closed tube, askthe patient to2h in order to turn over, to facilitate the drug distribution, open thedrainage tube after48hours, again3days later is pumped to the chest water injection,after removal of chest lead governance therapy. The two groups were treated2timeseach week,2times for a course of treatment, were observed during no nausea andvomiting gastrointestinal reaction, in48hours after injection of second times within theliver and kidney function, blood routine examination, electrocardiogram, chest X-ray orchest B ultrasound reexamination after January.Results: The treatment group of22cases, pleural effusion in complete remission (CR)in4cases (18.18%), partial remission (PR) in12cases (54.55%), invalid (NC) in6cases (27.27%), the total efficiency (CR+PR) for (72.73%).The single agent cisplatingroup,19cases of pleural effusion in complete remission (CR) in2cases (7.69%),partial remission (PR) in9cases (34.62%), invalid (NC) in15cases (57.69%), the totalefficiency (CR+PR) for (42.31%). The two groups with X2=4.481(P<0.05, α=0.05),the difference was statistically significant.According to the change of KPS score beforeand after the treatment, the treatment group quality of life (QOL) improved in15cases(68.18%), stable in4cases (18.18%), decreased in3cases (13.64%), the totalimprovement rate86.36%. The quality of life of single agent cisplatin group (QOL)improvement in10cases (38.46%), stable in5cases (19.23%), decreased in11cases(42.31%), the total improvement rate57.69%.Two groups of the quality of life wasimproved compared with X2=4.742(P<0.05, α=0.05), the difference was statisticallysignificant,t he clinical symptoms of two groups of patients such as cough, sputum,difficulty breathing, chest pain and anorexia and significantly ease.The main side effectswere nausea and vomiting and other gastrointestinal reaction, bone marrow suppression,liver and kidney dysfunction. The treatment group,3cases of bone marrow suppression, 2cases of liver damage,8cases of gastrointestinal reaction,4cases of chest pain, thesingle agent cisplatin group,3cases of bone marrow suppression,3cases of liverdamage,9cases of gastrointestinal changes,5patients with chest pain, no abnormalECG, diarrhea, fever occurred in both two groups.Conclusion:Efficacy of Endostar combined with cisplatin in the treatment of pleuraleffusion caused by lung cancer, patients’ quality of life was improved, and patients onthe drug was well tolerated, with mild adverse reactions.Compared with the single agentcisplatin group, malignant pleural effusion treatment effective rate and quality of life ofpatients were improved obviously higher than the control group, there were statisticallysignificant differences, and compared with the single agent cisplatin group, did notincrease the adverse reaction, two groups of adverse reaction showed no statisticalsignificance, therefore, the characteristics of Endostar combined with cisplatin in thetreatment of cancer with high efficiency and low toxicity pleural effusion.